$39.53
1.50% today
Nasdaq, Nov 04, 09:15 pm CET
ISIN
US00847X1046
Symbol
AGIO

Agios Pharmaceuticals, Inc. Stock price

$40.13
-0.37 0.91% 1M
+10.16 33.90% 6M
+7.27 22.12% YTD
-4.70 10.48% 1Y
+13.77 52.24% 3Y
-1.32 3.18% 5Y
-38.28 48.82% 10Y
+8.85 28.29% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
-3.11 7.19%
ISIN
US00847X1046
Symbol
AGIO
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$1.4b
Net debt
positive
Cash
$938.9m
Shares outstanding
58.0m
Valuation (TTM | estimate)
P/E
3.6 | negative
P/S
57.2 | 51.8
EV/Sales
34.3 | 31.0
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
92.7%
Return on Equity
43.7%
ROCE
44.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$40.9m | $45.2m
EBITDA
$632.9m | $-496.4m
EBIT
$627.6m | $-499.6m
Net Income
$650.1m | $-438.2m
Free Cash Flow
$-409.0m
Growth (TTM | estimate)
Revenue
30.6% | 23.8%
EBITDA
258.6% | -18.2%
EBIT
254.9% | -17.4%
Net Income
278.1% | -165.1%
Free Cash Flow
-33.0%
Margin (TTM | estimate)
Gross
88.2%
EBITDA
1,548.3% | -1,099.0%
EBIT
1,535.4%
Net
1,590.4% | -970.2%
Free Cash Flow
-1,000.7%
More
EPS
$11.2
FCF per Share
$-7.0
Short interest
8.6%
Employees
487
Rev per Employee
$70.0k
Show more

Is Agios Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Agios Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Agios Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
41 41
31% 31%
100%
- Direct Costs 4.83 4.83
45% 45%
12%
36 36
29% 29%
88%
- Selling and Administrative Expenses 178 178
39% 39%
435%
- Research and Development Expense 320 320
5% 5%
783%
633 633
259% 259%
1,548%
- Depreciation and Amortization 5.25 5.25
12% 12%
13%
EBIT (Operating Income) EBIT 628 628
255% 255%
1,535%
Net Profit 650 650
278% 278%
1,590%

In millions USD.

Don't miss a Thing! We will send you all news about Agios Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agios Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
about 14 hours ago
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd's thalassemia sNDA in December 2025 and topline data from the 'RISE UP' sickle cell trial. Despite premium valuation, the company maintains a robust balance sheet and is positioned for significant ...
Neutral
GlobeNewsWire
one day ago
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activator, will be featured in oral and poster presentations during the 67th American Society of Hematology...
Neutral
Seeking Alpha
5 days ago
Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Al...
More Agios Pharmaceuticals, Inc. News

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Goff
Employees 487
Founded 2007
Website www.agios.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today